Description: Nova Mentis Life Science Corp., through its subsidiaries, focuses on developing medicinal psychedelics for neuroinflammatory conditions with a focus on autism spectrum disorder. It is also involved in the research and development of psychedelic medicines for metabolic indications, such as obesity and diabetes. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Home Page: www.novamentis.ca
700-838 West Hasting Street
Vancouver,
BC
V6C 0A6
Canada
Phone:
778 819 0244
Officers
| Name | Title |
|---|---|
| Mr. William Rascan | Pres, CEO & Director |
| Ms. Rebecca Lynn Hudson C.A., CPA, CA, CPA | Chief Financial Officer |
| Ms. Jacqueline McConnell | COO & Director |
| Dr. Stephen Glazer | Chief Science Officer & Director |
| Dr. Aylia Mohammadi B.Sc., M.Sc., Ph.D. | Pres & Chief Scientific Officer of Nova Mentis Biotech Corp. |
| Ms. Kelly Pladson | Corp. Sec. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.682 |
| Price-to-Sales TTM: | 5730.6973 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |